Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.

Friedman AJ, Rein MS, Pandian MR, Barbieri RL

Fertility and sterility1 Feb 1990Cited by 25 (Europe PMC)

PMID2105242DOI10.1016/s0015-0282(16)53276-2PepBankPUB-02105242

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, mean uterine volume decreased by 34% with leuprolide.
In plain wordsIn women with fibroids, mean uterine volume decreased with leuprolide.
Peptide
Leuprolide
Outcome
DecreaseUterine volume
Study
n = 9
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
3.75 mg every 4 weeks for four injections · intramuscularAs given in this study (human).
Measurements
Uterine volume reduction
34%
leuprolide
Source sentences
Summary
Leuprolide acetate treated patients demonstrated a reduction in mean uterine volume of 34% and a decrease in serum estradiol (E2) concentrations from 120 +/- 21 pg/mL (mean +/- standard error) to 16 +/- 9 pg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections.
Report a problemFND-0210524201
02HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, serum estradiol decreased from 120 +/- 21 to 16 +/- 9 pg/mL with leuprolide.
In plain wordsIn women with fibroids, blood estradiol decreased with leuprolide.
Peptide
Leuprolide
Outcome
DecreaseEstradiol
Study
n = 9
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks for four injections · intramuscularAs given in this study (human).
Measurements
Estradiol
120 pg/mL
baseline mean; standard error 21
Estradiol
16 pg/mL
posttreatment mean; standard error 9
Source sentences
Summary
Leuprolide acetate treated patients demonstrated a reduction in mean uterine volume of 34% and a decrease in serum estradiol (E2) concentrations from 120 +/- 21 pg/mL (mean +/- standard error) to 16 +/- 9 pg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections.
Report a problemFND-0210524202
03HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, serum growth hormone decreased significantly from 3.0 +/- 0.4 to 1.4 +/- 0.4 ng/mL with leuprolide.
In plain wordsIn women with fibroids, blood growth hormone decreased significantly during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseGrowth hormone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks for four injections · intramuscular · 12 weeksAs given in this study (human).
Measurements
GH
3 ng/mL
before; standard error 0.4
GH
1.4 ng/mL
after; standard error 0.4
Source sentences
Summary
Leuprolide acetate treated patients also demonstrated significant decreases in serum growth hormone (GH) (3.0 +/- 0.4 ng/mL versus 1.4 +/- 0.4 ng/mL) and insulin-like growth factor-I (IGF-I) concentrations (3.3 +/- 0.4 U/mL versus 1.3 +/- 0.2 U/mL) over the 12 week treatment period.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections.
Report a problemFND-0210524203
04HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, serum IGF-I decreased significantly from 3.3 +/- 0.4 to 1.3 +/- 0.2 U/mL with leuprolide.
In plain wordsIn women with fibroids, blood IGF-I decreased significantly during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseIGF-I
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks for four injections · intramuscular · 12 weeksAs given in this study (human).
Measurements
IGF-I
3.3 U/mL
before; standard error 0.4
IGF-I
1.3 U/mL
after; standard error 0.2
Source sentences
Summary
Leuprolide acetate treated patients also demonstrated significant decreases in serum growth hormone (GH) (3.0 +/- 0.4 ng/mL versus 1.4 +/- 0.4 ng/mL) and insulin-like growth factor-I (IGF-I) concentrations (3.3 +/- 0.4 U/mL versus 1.3 +/- 0.2 U/mL) over the 12 week treatment period.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections.
Report a problemFND-0210524204
05HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, serum IGF-II did not change with leuprolide.
In plain wordsIn women with fibroids, blood IGF-II did not change with leuprolide.
Peptide
Leuprolide
Outcome
No significant changeIGF-II
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks for four injections · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
Serum IGF-II levels did not change.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections.
Report a problemFND-0210524205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms